Skip to Content

EADV 2026: Treatment With Semaglutide Lowers the Risk of Developing Psoriasis Compared to Liraglutide

Nikolai Nguyen Loft, MD, PhD, Research Leader at the University of Copenhagen and the Department of Dermatology at Gentofte Hospital, presents findings from a Danish nationwide cohort study investigating the risk of developing psoriasis in patients treated with semaglutide or liraglutide for type 2 diabetes and/or obesity. Using Danish national registries, the study provides observational data on the potential association between better obesity and diabetic control and a lower risk of developing psoriasis.

Nikolai Nguyen Loft

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top